Partnering with Japanese Pharmaceutical Companies

3/12/2008

Life Sciences

Palo Alto, CA

Stephen B. Thau

Stephen B. Thau

Seminar

Takeda’s $1 Billion acquisition of Japanese rights to Amgen’s drugs is the latest high profile transaction between a U.S. biotech and a Japanese pharmaceutical company.

Over the past several years, transactions with Japanese pharmaceutical companies have provided access to new markets, financial capital, and intellectual property rights for compounds for development.

Our panel of experts will discuss how to initiate, negotiate and execute a successful relationship with a Japanese pharmaceutical company.

Topics will include:

  • Overview of Market Trends
  • Anatomy of the Amgen/Takeda Deal
  • Structuring Deals with Japanese Pharmaceutical Companies
  • What makes for a Successful Negotiation Between U.S. and Japanese Companies

Speakers will include:

Benson Fong, President & CEO , Lapis Therapeutics, Inc.; former SVP Corporate Development, CoTherix, Inc.
Mr. Fong identified a clinical stage asset from Asahi Kasei Pharma and with Morrison & Foerster negotiated a license agreement for U.S. and European rights.

William Hodder, Vice President, Business Development, FibroGen, Inc.
Mr. Hodder orchestrated FibroGen, Inc.’s anemia transactions with Japan’s Yamanouchi and its successor, Astellas Pharma Inc.

Jonathan D. Dickstein, Morrison & Foerster San Francisco Partner
Mr. Dickstein has represented a variety of biotechnology, medical device, and pharmaceutical companies in a broad range of transactions, including inbound and outbound licensing, drug discovery and development deals, joint research and development collaborations, manufacture and supply arrangements, distribution and reseller relationships, co-marketing agreements, outsourcing projects, strategic joint ventures, and mergers and acquisitions.

Stephen B. Thau, Morrison & Foerster Palo Alto Partner
Mr. Thau’s practice focuses on the representation of life science, medical device, and other technology companies at all stages of their life cycles, from company formation, equity and debt financing, merger and acquisition transactions, strategic alliances, and public offerings. He has represented companies and investors in over a hundred venture capital and debt financing transactions, as well as in numerous public offerings and public and private M&A transactions.

Mark R. Wicker, Morrison & Foerster San Diego Partner
Mr. Wicker represents entrepreneurs, startup ventures, established companies, and investors in the technology and life science industries in all aspects of their business. He specializes in structuring and negotiating creative and effective arrangements for the research, development, and commercialization of products and technologies, including joint ventures, corporate partnerships, licenses, contract research and manufacturing, and other strategic alliances.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.